Document is current
Any future updates will be listed below
-
Authors
Jiang, Richeng http://orcid.org/0000-0001-5184-4172
Smailovic, Una
Haytural, Hazal
Tijms, Betty M.
Li, Hao
Haret, Robert Mihai
Shevchenko, Ganna
Chen, Gefei
Abelein, Axel
Gobom, Johan
Frykman, Susanne
Sekiguchi, Misaki
Fujioka, Ryo
Watamura, Naoto
Sasaguri, Hiroki
Nyström, Sofie
Hammarström, Per
Saido, Takaomi C.
Jelic, Vesna
Syvänen, Stina
Zetterberg, Henrik
Winblad, Bengt
Bergquist, Jonas
Visser, Pieter Jelle
Nilsson, Per http://orcid.org/0000-0001-6450-0870
-
Funding
Funding for this research was provided by:
Bertil Hållstens Forskningsstiftelse
Alzheimerfonden
Hjärnfonden
Vetenskapsrådet
Karolinska Institute
- License Information
-
More Information
Article History
Received: 10 March 2022
Accepted: 18 June 2022
First Online: 4 July 2022
Declarations
:
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors declare no competing interests.
